ZYME PE Ratio & Valuation,Is ZYME Overvalued

ZYME Relative Valuation

ZYME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZYME is overvalued; if below, it's undervalued.

Historical Valuation

Zymeworks Inc (ZYME) is now in the Undervalued zone, suggesting that its current forward PS ratio of 19.60 is considered Undervalued compared with the five-year average of -3.82. The fair price of Zymeworks Inc (ZYME) is between 158.45 to 165.67 according to relative valuation methord. Compared to the current price of 25.48 USD , Zymeworks Inc is Undervalued By 83.92%.

Relative Value

Fair Zone

158.45-165.67

Current Price：25.48

83.92%

Undervalued

-27.48

205.80

EV/EBITDA

Zymeworks Inc. (ZYME) has a current EV/EBITDA of 205.80. The 5-year average EV/EBITDA is 3.61. The thresholds are as follows: Strongly Undervalued below -63.42, Undervalued between -63.42 and -29.91, Fairly Valued between 37.13 and -29.91, Overvalued between 37.13 and 70.64, and Strongly Overvalued above 70.64. The current Forward EV/EBITDA of 205.80 falls within the Strongly Overvalued range.

-16.09

EV/EBIT

Zymeworks Inc. (ZYME) has a current EV/EBIT of -16.09. The 5-year average EV/EBIT is -3.37. The thresholds are as follows: Strongly Undervalued below -10.52, Undervalued between -10.52 and -6.94, Fairly Valued between 0.20 and -6.94, Overvalued between 0.20 and 3.77, and Strongly Overvalued above 3.77. The current Forward EV/EBIT of -16.09 falls within the Strongly Undervalued range.

19.60

Zymeworks Inc. (ZYME) has a current PS of 19.60. The 5-year average PS is 18.93. The thresholds are as follows: Strongly Undervalued below -38.00, Undervalued between -38.00 and -9.54, Fairly Valued between 47.39 and -9.54, Overvalued between 47.39 and 75.85, and Strongly Overvalued above 75.85. The current Forward PS of 19.60 falls within the Historic Trend Line -Fairly Valued range.

-43.09

P/OCF

Zymeworks Inc. (ZYME) has a current P/OCF of -43.09. The 5-year average P/OCF is -15.19. The thresholds are as follows: Strongly Undervalued below -504.78, Undervalued between -504.78 and -259.99, Fairly Valued between 229.60 and -259.99, Overvalued between 229.60 and 474.40, and Strongly Overvalued above 474.40. The current Forward P/OCF of -43.09 falls within the Historic Trend Line -Fairly Valued range.

21.55

P/FCF

Zymeworks Inc. (ZYME) has a current P/FCF of 21.55. The 5-year average P/FCF is -3.96. The thresholds are as follows: Strongly Undervalued below -37.01, Undervalued between -37.01 and -20.49, Fairly Valued between 12.56 and -20.49, Overvalued between 12.56 and 29.08, and Strongly Overvalued above 29.08. The current Forward P/FCF of 21.55 falls within the Overvalued range.

Zymeworks Inc (ZYME) has a current Price-to-Book (P/B) ratio of 5.98. Compared to its 3-year average P/B ratio of 2.09 , the current P/B ratio is approximately 185.84% higher. Relative to its 5-year average P/B ratio of 2.47, the current P/B ratio is about 142.39% higher. Zymeworks Inc (ZYME) has a Forward Free Cash Flow (FCF) yield of approximately -3.43%. Compared to its 3-year average FCF yield of 2.82%, the current FCF yield is approximately -221.67% lower. Relative to its 5-year average FCF yield of -12.23% , the current FCF yield is about -71.90% lower.

5.98

P/B

Median3y

2.09

Median5y

2.47

-3.43

FCF Yield

Median3y

2.82

Median5y

-12.23

Competitors Valuation Multiple

The average P/S ratio for ZYME's competitors is 247.39, providing a benchmark for relative valuation. Zymeworks Inc Corp (ZYME) exhibits a P/S ratio of 19.60, which is -92.08% above the industry average. Given its robust revenue growth of 72.59%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ZYME increased by 74.04% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 16.00M to 27.61M.

The secondary factor is the P/E Change, contributed 63.40%to the performance.

Overall, the performance of ZYME in the past 1 year is driven by Revenue Growth. Which is more sustainable.

72.59%

16.00M → 27.61M

Revenue Growth

-61.95%

-186.56 → -70.99

Margin Expansion

63.40%

-18.50 → -30.23

P/E Change

74.04%

14.64 → 25.48

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Zymeworks Inc (ZYME) currently overvalued or undervalued?

What is Zymeworks Inc (ZYME) fair value?

ZYME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Zymeworks Inc (ZYME) is between 158.45 to 165.67 according to relative valuation methord.

How does ZYME's valuation metrics compare to the industry average?

What is the current P/B ratio for Zymeworks Inc (ZYME) as of Dec 15 2025?

As of Dec 15 2025, Zymeworks Inc (ZYME) has a P/B ratio of 5.98. This indicates that the market values ZYME at 5.98 times its book value.

What is the current FCF Yield for Zymeworks Inc (ZYME) as of Dec 15 2025?

As of Dec 15 2025, Zymeworks Inc (ZYME) has a FCF Yield of -3.43%. This means that for every dollar of Zymeworks Inc’s market capitalization, the company generates -3.43 cents in free cash flow.

What is the current Forward P/E ratio for Zymeworks Inc (ZYME) as of Dec 15 2025?

As of Dec 15 2025, Zymeworks Inc (ZYME) has a Forward P/E ratio of -27.48. This means the market is willing to pay $-27.48 for every dollar of Zymeworks Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zymeworks Inc (ZYME) as of Dec 15 2025?

As of Dec 15 2025, Zymeworks Inc (ZYME) has a Forward P/S ratio of 19.60. This means the market is valuing ZYME at $19.60 for every dollar of expected revenue over the next 12 months.

ZYME Valuation